Poland· PL-100438911
Reblozyl
A luspatercept product containing luspaterceptum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Luspatercept is registered in 14 of 19 countries.
Countries holding a registration under ATC B03XA06 (luspatercept), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Luspatercept · ATC B03XA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Luspaterceptum
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Poland (PL)
- ATC code
- B03XA06
- ATC class
- Luspatercept
- Defined daily dose
- 3.33 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07640133688244
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Luspatercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumReblozyl 25 mgBristol-Myers Squibb Pharma
- SwitzerlandReblozyl 25 mg, Pulver zur Herstellung einer InjektionslösungBristol-Myers Squibb SA
- CzechiaREBLOZYLBristol-Myers Squibb Pharma EEIG, Dublin
- SpainREBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLEBristol-Myers Squibb Pharma Eeig
- IcelandReblozylBristol-Myers Squibb Pharma EEIG*
- NorwayReblozylBristol-Myers Squibb Pharma EEIG (1)
- SwedenReblozyl 25 mg Pulver till injektionsvätska, lösningBristol-Myers Squibb Pharma EEIG
- United StatesReblozylCelgene Corporation
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Reblozyl
- Liechtenstein · Reblozyl
- Norway · Reblozyl
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8bf1a0da-d9b5-4c89-8177-98496db4bedd GET /v1/drugs/8bf1a0da-d9b5-4c89-8177-98496db4bedd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "25 mg",
"packaging": "07640133688244 ¦ Rpz ¦ EU/1/20/1452/001 ¦ 137066\n1 fiol. proszku\n¦ UR/Z/4b/135/24 - 07640133688244 ¦ UR/Z/4b/193/25 - 07640133688244",
"substance": null,
"common_name": "Luspaterceptum",
"pl_product_id": "100438911",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about luspatercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.